TrialEuropean journal of haematology2026

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study.

Margareth C Ozelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.